What is the address of Docteur EL ALI Ziad Oncologie Médicale?

The registered office of Docteur EL ALI Ziad Oncologie Médicale is located at Maria-Louizasquare 18 box 12, 1000 Brussel.

Is Docteur EL ALI Ziad Oncologie Médicale still active?

Yes. According to the CBE (28 September 2026) Docteur EL ALI Ziad Oncologie Médicale is active, legal situation “Normale toestand”, started on 1 April 2020.

Is Docteur EL ALI Ziad Oncologie Médicale registered on Peppol?

Yes, Docteur EL ALI Ziad Oncologie Médicale is registered on the Peppol network with ID 0208:0745761932.

What is the enterprise number of Docteur EL ALI Ziad Oncologie Médicale?

The enterprise number of Docteur EL ALI Ziad Oncologie Médicale is BE0745761932.

When was Docteur EL ALI Ziad Oncologie Médicale founded?

Docteur EL ALI Ziad Oncologie Médicale was founded on 1 April 2020.

Who are the directors of Docteur EL ALI Ziad Oncologie Médicale?

According to the 2025 annual accounts, the directors of Docteur EL ALI Ziad Oncologie Médicale are: EL ALI ZIAD.

Is Docteur EL ALI Ziad Oncologie Médicale a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 April 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Docteur EL ALI Ziad Oncologie Médicale make in 2025?

Docteur EL ALI Ziad Oncologie Médicale posted a profit after taxes of € 60,200 in financial year 2025.

What is the revenue of Docteur EL ALI Ziad Oncologie Médicale?

As a small company, Docteur EL ALI Ziad Oncologie Médicale is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 125,832.

Docteur EL ALI Ziad Oncologie Médicale (Private Limited)

Dossier Docteur EL ALI Ziad Oncologie Médicale, printed on 28 September 2026 from databakkes.be/en/0745761932/docteur-el-ali-ziad-oncologie-medicale. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Docteur EL ALI Ziad Oncologie Médicale from Brussel, company number BE0745761932, closed financial year 2025 with a result of € 60,200 after tax. For that financial year Docteur EL ALI Ziad Oncologie Médicale recorded a gross margin of € 125,832 and equity of € 127,699. Compared with financial year 2024, the result moved from € 53,684 to € 60,200. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 30, 2026.

What it is worth Healthy

€ 127,699

▼ 30% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 60,200

▲ 12% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 102,479

▲ 8% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 114,902 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 30

▼ € 6,093 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 38,616

▼ 25% vs 2024

€ 13,392 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 123,970 Gross margin 2022: € 123,970 First fiscal year in the series	€ 111,360 Gross margin 2023: € 111,360 ▼ 10% vs 2022 (€ 123,970) Unfavourable step	€ 117,489 Gross margin 2024: € 117,489 ▲ 6% vs 2023 (€ 111,360) Favourable step	€ 125,832 Gross margin 2025: € 125,832 ▲ 7% vs 2024 (€ 117,489) Favourable step	▲ 7%
Profit after taxes	€ 58,043 Profit after taxes 2022: € 58,043 First fiscal year in the series	€ 46,584 Profit after taxes 2023: € 46,584 ▼ 20% vs 2022 (€ 58,043) Unfavourable step	€ 53,684 Profit after taxes 2024: € 53,684 ▲ 15% vs 2023 (€ 46,584) Favourable step	€ 60,200 Profit after taxes 2025: € 60,200 ▲ 12% vs 2024 (€ 53,684) Favourable step	▲ 12%
Equity	€ 182,401 Equity 2022: € 182,401 First fiscal year in the series	€ 182,401 Equity 2023: € 182,401 Unchanged (€ 182,401) Unchanged	€ 182,401 Equity 2024: € 182,401 Unchanged (€ 182,401) Unchanged	€ 127,699 Equity 2025: € 127,699 ▼ 30% vs 2024 (€ 182,401) Unfavourable step	▼ 30%
Total debts	€ 176,314 Total debts 2022: € 176,314 First fiscal year in the series	€ 128,720 Total debts 2023: € 128,720 ▼ 27% vs 2022 (€ 176,314) Favourable step	€ 107,744 Total debts 2024: € 107,744 ▼ 16% vs 2023 (€ 128,720) Favourable step	€ 153,519 Total debts 2025: € 153,519 ▲ 42% vs 2024 (€ 107,744) Unfavourable step	▲ 42%
Cash	€ 83,940 Cash 2022: € 83,940 First fiscal year in the series	€ 83,125 Cash 2023: € 83,125 ▼ 1% vs 2022 (€ 83,940) Unfavourable step	€ 94,893 Cash 2024: € 94,893 ▲ 14% vs 2023 (€ 83,125) Favourable step	€ 102,479 Cash 2025: € 102,479 ▲ 8% vs 2024 (€ 94,893) Favourable step	▲ 8%
Retained profit	€ 182,401 Retained profit 2022: € 182,401 First fiscal year in the series	€ 182,401 Retained profit 2023: € 182,401 Unchanged (€ 182,401) Unchanged	€ 182,401 Retained profit 2024: € 182,401 Unchanged (€ 182,401) Unchanged	€ 127,699 Retained profit 2025: € 127,699 ▼ 30% vs 2024 (€ 182,401) Unfavourable step	▼ 30%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 46,584 Dividend 2023: € 46,584 Unchanged (€ 0) Unchanged	€ 53,684 Dividend 2024: € 53,684 ▲ 15% vs 2023 (€ 46,584) Unchanged	€ 114,902 Dividend 2025: € 114,902 ▲ 114% vs 2024 (€ 53,684) Unchanged	▲ 114%
Bank debt	€ 77,224 Bank debt 2022: € 77,224 First fiscal year in the series	€ 64,883 Bank debt 2023: € 64,883 ▼ 16% vs 2022 (€ 77,224) Favourable step	€ 51,744 Bank debt 2024: € 51,744 ▼ 20% vs 2023 (€ 64,883) Favourable step	€ 38,616 Bank debt 2025: € 38,616 ▼ 25% vs 2024 (€ 51,744) Favourable step	▼ 25%
Balance sheet total	€ 358,716 Balance sheet total 2022: € 358,716 First fiscal year in the series	€ 311,122 Balance sheet total 2023: € 311,122 ▼ 13% vs 2022 (€ 358,716) Unchanged	€ 290,146 Balance sheet total 2024: € 290,146 ▼ 7% vs 2023 (€ 311,122) Unchanged	€ 281,218 Balance sheet total 2025: € 281,218 ▼ 3% vs 2024 (€ 290,146) Unchanged	▼ 3%

Key figures of Docteur EL ALI Ziad Oncologie Médicale, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Docteur EL ALI Ziad Oncologie Médicale?

What happened at Docteur EL ALI Ziad Oncologie Médicale in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 30, 2026 New annual accounts for financial year 2025: profit of € 60,200 (▲ 12% vs 2024). Source: NBB ↗
Apr 1, 2020 New establishment in Brussel. KBO
Apr 1, 2020 Start of the company according to the CBE. KBO

In short

From € 58,043 profit in 2022 to € 60,200 profit in 2025.

Paid € 66,843 in corporate taxes since 2022.

Best year ever: 2025, with € 60,200 profit.

Paid out € 215,170 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Docteur EL ALI Ziad Oncologie Médicale? We notify you, reason included.

Follow Docteur EL ALI Ziad Oncologie Médicale

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

EL ALI ZIAD

Docteur EL ALI Ziad Oncologie Médicale

Behind Docteur EL ALI Ziad Oncologie Médicale is EL ALI ZIAD.

See the full network in the app

Directors

According to the 2025 annual accounts

EL ALI ZIAD

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Maria-Louizasquare 18 box 12

1000 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Groupement des Fédérations des Industries graphiques dans les Communautés européennes

Women in Energy, Climate and Sustainability

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0745.761.932
VAT number: BE 0745.761.932
Registered office: Maria-Louizasquare 18 bus 12, 1000 Brussel
Names & denominations: Docteur EL ALI Ziad Oncologie Médicale
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 1 April 2020
Peppol: Active · Active since 19 Mar 2026

View on CBE Public ↗ Annual accounts (NBB) ↗